#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypergammaglobulinaemia benign monoclonal Crigler-Najjar syndrome Biliary neoplasm Peritoneal mesothelioma malignant Dermatomyositis Neuroendocrine carcinoma Chondrodystrophy Cerebellar ataxia Prodromal Alzheimer's disease Kaposi's sarcoma Haemophilia A with anti factor VIII Cholangitis sclerosing Congenital leptin deficiency Osteosarcoma recurrent Craniopharyngioma More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Basic Information Nodal marginal zone B-cell lymphoma – Treatment Hairy cell leukaemia recurrent Primary biliary cholangitis – Trials in Disease Waldenstrom’s macroglobulinaemia – Diagnostics Retinitis pigmentosa Uterine leiomyosarcoma – Life with Disease Alexander disease – Trials in Disease Hairy cell leukaemia Netherton’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VTX-002 ZILUCOPLAN Irinotecan Hydrochloride 4-Hydroxy-N-Desmethyltamoxifen MAPLIRPACEPT Tafluprost Ibrutinib Io102 Hydrochloride Human Cancellous Bone Davutamig Donepezil Hydrochloride Botensilimab Sacubitril Valsartan ORG-129 Ofatumumab Lenacapavir Gad20-209-Fsp-A4 Fluvastatin Diclofenac Sodium Sertindole More therapies…

    Learn about Your Condition

    Hypercholesterolaemia Laparotomy Primary hyperthyroidism Osteochondrodysplasia Migraine with aura Pulmonary resection Ventricular fibrillation Bronchopulmonary aspergillosis Transitional cell carcinoma Obesity Enteritis Advanced systemic mastocytosis Henoch-Schonlein purpura Polymyalgia rheumatica Tooth loss More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Antoine Lacassagne

Centre Antoine Lacassagne

33 Avenue De Valombrose, Nice, 06189, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    • Lutetium (177Lu) Oxodotreotide
    France

  • Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France

  • Study on Everolimus and Lutetium (177Lu) Oxodotreotide for Treating Grades 2 and 3 Refractory Meningioma in Patients

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • Everolimus
    France

  • Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ibrutinib
    • Pirtobrutinib
    Austria Belgium Czechia France Germany Hungary +3

  • Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Ibrutinib
    • Lisaftoclax
    Belgium Bulgaria Czechia France Germany Hungary +5

  • Study comparing preoperative drug combination with irinotecan, fluorouracil, calcium folinate and oxaliplatin for patients with locally advanced resectable rectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Irinotecan Hydrochloride
    France

  • Study of Atezolizumab After Chemo-radiotherapy for Patients with Muscle-invasive Bladder Cancer Not Eligible for Radical Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    France

  • Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Triptorelin
    • Darolutamide
    France Spain

  • Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Paclitaxel
    • Pembrolizumab
    France Spain

  • Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Tucatinib
    • Bevacizumab
    • Cetuximab
    Austria Belgium France Germany Greece Hungary +8
Previous Page
1 … 7 8 9 10 11 … 28
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!